However, a preoperative CEA of 10 ng/mL has been advanced as the optimal level for assessing recurrence risk in CRC patients with stage II and III, but not stage I, according to a study of 638 stage I–III CRC patients after curative surgery [34]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.